These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28403027)

  • 21. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Snopková S; Havlíčková K; Husa P
    Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Epi-TAF for Tenofovir Disoproxil Fumarate?
    Walensky RP; Horn TH; Paltiel AD
    Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    Gupta SK; Post FA; Arribas JR; Eron JJ; Wohl DA; Clarke AE; Sax PE; Stellbrink HJ; Esser S; Pozniak AL; Podzamczer D; Waters L; Orkin C; Rockstroh JK; Mudrikova T; Negredo E; Elion RA; Guo S; Zhong L; Carter C; Martin H; Brainard D; SenGupta D; Das M
    AIDS; 2019 Jul; 33(9):1455-1465. PubMed ID: 30932951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Update in HIV therapy: tenofovir alafenamide].
    Sauvage AS; Darcis G; Moutschen M
    Rev Med Suisse; 2016 Aug; 12(527):1367-1369. PubMed ID: 28671790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
    Shafran SD; Di Perri G; Esser S; Lelièvre JD; Parczewski M
    HIV Med; 2019 Jun; 20 Suppl 7():1-16. PubMed ID: 31099116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
    Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
    HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
    [No Abstract]   [Full Text] [Related]  

  • 30. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
    HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir alafenamide use in pregnant and lactating women living with HIV.
    Eke AC; Brooks KM; Gebreyohannes RD; Sheffield JS; Dooley KE; Mirochnick M
    Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):333-342. PubMed ID: 32125906
    [No Abstract]   [Full Text] [Related]  

  • 32. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
    Lee SS; Havens JP; Sayles HR; O'Neill JL; Podany AT; Swindells S; Scarsi KK; Bares SH
    BMC Infect Dis; 2018 Jul; 18(1):310. PubMed ID: 29980192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
    Lacey A; Savinelli S; Barco EA; Macken A; Cotter AG; Sheehan G; Lambert JS; Muldoon E; Feeney E; Mallon PW; Tinago W;
    AIDS; 2020 Jul; 34(8):1161-1170. PubMed ID: 32310899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
    AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
    Mikula JM; Manion MM; Maldarelli F; Suarez LM; Norman-Wheeler JF; Ober AG; Dewar RL; Kopp JB; Lane HC; Pau AK
    Antivir Ther; 2016; 21(6):553-558. PubMed ID: 26954372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study.
    Soldado-Folgado J; Rins-Lozano O; Arrieta-Aldea I; Gonzále-Mena A; Cañas-Ruano E; Knobel H; Garcia-Giralt N; Güerri-Fernández R
    Front Endocrinol (Lausanne); 2023; 14():1076739. PubMed ID: 37051195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.